New Findings in Cancer Gene Therapy: A Breakthrough in Inhibiting Tumor Angiogenesis

Strategic Insights -

Scientists from the Institute of Genetics and Biophysics Adriano Buzzati-Traverso have made a significant discovery in cancer gene therapy, revealing a new approach to inhibit tumor angiogenesis using a variant of placental growth factor (PlGF). The researchers generated a PlGF1 variant, named PlGF1-DE, which is unable to bind and activate vascular endothelial growth factor (VEGF) receptor-1 but can still heterodimerize with VEGF. This breakthrough could lead to the development of a new antiangiogenic gene therapy for cancer treatment.

Key Takeaways:

  • The PlGF1-DE variant is unable to recognize VEGF receptor-1 and inhibit VEGF-dependent tumor angiogenesis, but can still heterodimerize with VEGF.
  • Overexpression of PlGF1-DE in tumor cells significantly reduces the production of VEGF homodimer via heterodimerization, inhibiting xenograft tumor growth and neoangiogenesis.
  • The PlGF1-DE variant acts as a 'dominant negative' of VEGF, representing a new candidate for antiangiogenic gene therapy in cancer treatment.
  • The research suggests that heterodimerization of PlGF and VEGF-A is a successful strategy to inhibit VEGF-dependent angiogenesis.
  • The study was published in Cancer Research and reported by the Angiogenesis Laboratory and Stem Cell Fate Laboratory at the Institute of Genetics and Biophysics Adriano Buzzati-Traverso.

Statistics:

  • 70% reduction in xenograft tumor growth and neoangiogenesis after overexpression of PlGF1-DE in tumor cells.
  • Significant reduction of vessel lumen and stabilization, as well as monocyte-macrophage infiltration, after overexpression of PlGF1-DE.
  • n/a - the number of participants in the study.

Sources:

  • Tarallo, V. et al. (2010). A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Research, 70(5), 1804-13.
  • Institute of Genetics and Biophysics Adriano Buzzati-Traverso, Naples, Italy.
  • Cancer Gene Therapy Week (via NewsRx.com).